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ABSTRAK 
Sumarningsih, Tarigan S, Hemmatzadeh F, Ignjatovic J. 2019. Antigenik karakterisasi pada protein M2e menggunakan antibodi 
monoklonal anti-M2 dan antibodi poliklonal anti-M2e. JITV 24(3): 122-134. DOI: http://dx.doi.org.10.14334/jitv.v24i3.1987 
Protein Matrik 2 ektodomain (M2e) memiliki sifat lestari dan dianggap sebagai antigen potensial untuk mendeteksi infeksi 
virus influenza A pada unggas yang divaksinasi (DIVA test). Namun studi yang mempelajari antigenisitas M2 dan respon imun 
pada manusia atau hewan masih sangat terbatas. Pada studi ini sifat antigenik dari masing-masing tujuh belas M2e peptida dan 
enam belas protein rekombinan M2e (rM2e) yang memiliki variasi asam amino (aa) pada posisi 10, 11, 12, 13, 14, 16, 18 dan 20 
dibandingkan dengan metode western blot (WB) dan enzyme-linked immunosorbent assay (ELISA) menggunakan antibodi 
monoklonal (mAb) 14C2 dari tikus, dan anti-M2e poliklonal antibody (pAb) yang berasal dari ayam dan kelinci. MAb 14C2 
memiliki kekuatan pembeda terbaik dan aa posisi ke-11 merupakan imunodominan paling penting yang mempengaruhi ikatan 
mAb14C2 hingga tingkat yang terbesar. Perubahan pada posisi 14, 16 dan 18 juga mempengaruhi pengikatan mAb14C2, dan 
perubahan ini terdeteksi pada semua metode (WB atau ELISA) dan antigen yang digunakan (M2e peptida atau protein rM2e). 
Untuk anti-M2e pAb dari ayam dan kelinci, aa imunodominan ditemukan pada posisi 10 dan perubahan pada posisi 11 tidak 
mempengaruhi reaksi antibodi. Pengikatan pAb kelinci juga dipengaruhi oleh perubahan pada aa posisi 14 dan 16, hal ini 
mengkonfirmasi kontribusi posisi tersebut terhadap antigenisitas M2e. Posisi 10 adalah satu-satunya posisi yang penting untuk 
pengikatan pAb ayam terhadap M2e. Secara keseluruhan penelitian ini menunjukkan antigenik M2e terletak di antara residu 10 - 
18 dan perubahan aa pada posisi 10, 11, 12, 14, 16 dan 18, dapat mempengaruhi ikatan antibodi di dalam protein M2e. 
Kata kunci: Virus Influenza A, epitop M2e, antigenisitas 
ABSTRACT 
Sumarningsih, Tarigan S, Hemmatzadeh F, Ignjatovic J. 2019. Characterisation of M2e antigenicity using anti-M2 monoclonal 
antibody and anti-M2e polyclonal antibodies. JITV 24(3): 122-134. DOI: http://dx.doi.org.10.14334/jitv.v24.i3.1987 
Ectodomain matrix 2 protein (M2e) is a potential antigen for detection of influenza-A-virus infection among vaccinated 
birds (DIVA test). However, the antigenicity and immune response induced by M2e in either humans or animals are poorly 
understood. Seventeen M2e peptides and sixteen recombinant M2e (rM2e) proteins with amino acid (aa) changes introduced at 
position 10, 11, 12, 13 14, 16, 18 and 20 were compared by western blot (WB) and enzyme-linked immunosorbent assay 
(ELISA) using mouse anti-M2 monoclonal antibody (mAb) 14C2, and chicken- or rabbit-polyclonal antibodies (pAb). The mAb 
14C2 had the best discriminating power and aa position 11 was the important immunodominant for mAb14C2, that affected 
binding to a greatest degree. Changes in the adjacent position 14, 16 and 18 also influenced the binding, and it detected 
regardless of the method (WB or ELISA), or the antigen used (M2e peptide or rM2e). For chicken pAb and rabbit pAb, the 
immunodominant aa was position 10 and the antibody reaction was not affected by aa change at 11. The binding of rabbit pAb 
was also affected by changes at 14 and 16, which confirm the contribution of these positions to the M2e antigenicity. Position 10 
was the only important position for the binding of chicken pAb to M2e. Overall, the study showed that the M2e antigenic sites 
are located between residues 10 – 18 and that aa changes at position 10, 11, 12, 14, 16 and 18 may all affect the antibody binding 
within the M2e protein. 
Key Words: Influenza A Virus, M2e epitope, antigenicity 
INTRODUCTION 
Highly pathogenic avian influenza subtype H5N1, 
has continued to be a significant concern for more than 
a decade globally, and especially in several South East 
Asia countries where the virus has become endemic in 
commercial poultry. As fatalities in humans, which 
have been directly linked to contacts with infected 
poultry continue to occur, measure that would reduce 
virus load in the environment, such as vaccination, are 
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now practiced in several countries. In some countries 
additional measures are considered such as using the 
differentiation of infected from vaccinated animals 
(DIVA) test for use in surveillance of vaccinated flocks 
in order to estimate the extent of H5N1 challenge in 
vaccinated flocks. 
Ectodomain matrix 2 (M2e) protein is a 24 amino 
acid long protein located in the Matrix 2 (M2) protein 
N terminal. It is abundantly express on the cell surface 
infected by Influenza A virus (IAV), but very few are 
found in the virion of AIV (Lamb et al. 1985). Previous 
study, using mouse mAb 14C2 reported that M2e was 
the most important part for antigenicity of M2 protein 
as mAb 14C2 could not recognise the M2 lacking the 
ectodomain (M2e) protein (Zebedee & Lamb 1988). 
M2e protein is considered to be a potential antigen for 
DIVA test and high specificity of enzyme-linked 
immunosorbent assay (ELISA) using synthetic M2e-
peptide or recombinant M2e protein has been reported 
by several studies (Lambrecht et al. 2007; 
Hemmatzadeh et al. 2013; Tarigan et al. 2015). 
Although the M2e based DIVA test has been evaluated 
for possible use in commercial poultry (Lambrecht et 
al. 2007; Hemmatzadeh et al. 2013; Kim et al. 2010, 
Tarigan et al. 2015), very little is known about the 
antigenicity of the M2e and antibody response it 
induces in infected poultry. Limited studies, however, 
have been carried on M2e antigenicity and 
immunogenicity and these studies were mostly focused 
on the M2e responses in humans, mice, pigs or ferrets 
(Schotsaert et al. 2009). Those studies concluded that 
M2e was a poor immunogen and induced antibodies 
only in a fraction of infected individuals, and antibody 
titres were low and of short duration (Feng et al. 2006); 
(Kitikoon et al. 2008); (Bianchi et al. 2001). In 
addition, antigenic variations in the M2e protein have 
only been studied using monoclonal antibodies 
(Zharikova et al. 2005; Zebedee & Lamb 1988). 
In chickens, only limited studies have dealt with the 
immune responses to the M2e protein. An M2e-peptide 
based ELISA was used as a DIVA test to identify 
chickens and ducks challenged with HPAI viruses 
H5N1 and H7N7 (Hemmatzadeh et al. 2013: 
Lambrecht et al. 2007; Marché et al. 2010). Twenty-
four and eighteen amino acid long M2e peptides were 
recognised in ELISA by immune chicken sera 
indicating that on the M2e peptide at least some, if not 
all, antigenic domains are correctly presented. 
Although antibodies to M2e were detectable, they were 
not consistently detected and were absent in chicks 
infected with LPAI isolated from water birds. In 
another study it was also shown that the M2e-peptide 
based ELISA was able to detect infection with H9N2 
strain in vaccinated commercial poultry (Kim et al. 
2010). In these studies the synthetic M2e peptide and 
recombinant M2e (rM2e) coupled to maltose bonding 
protein (MBP) were used to assess the suitability of 
M2e as a DIVA reagent (Lambrecht et al. 2007; 
Hemmatzadeh et al. 2013), and in another study also as 
a vaccine candidate (Mozdzanowska et al. 2003). 
Overall, these studies have indicated that synthetic M2e 
peptide is suitable for DIVA, and rM2e may both be 
useful for antigenic mapping of the M2e. 
To date, limited report is available regarding M2e 
antigenicity in chickens or recognition of M2e by sera 
from various AIV infections (Lambrecht et al. 2007; 
Marché et al. 2010; Kim et al. 2010). For successful 
implementation of a DIVA test, it is critical to 
understand if M2e can be used as a universal detecting 
agent. Therefore, this study aimed to characterise the 
antigenic epitopes on M2e and identify critical 
mutations that influence binding of antisera to the M2e 
antigen. For this purpose, M2e-MBP recombinant 
proteins were generated as well as synthetic peptides 
carrying different mutations in the M2e protein, and 
used to analyse the M2e antigenic determinants. Two 
different immunological assays, WB and ELISA, were 
employed to achieve a comprehensive evaluation of 
M2e antigenicity using polyclonal antibodies (pAb) 
generated in chicken and rabbit against the M2eC0 
peptide. Monoclonal antibody (mAb) 14C2 was also 
purchased and used for antigenic characterisation and 
for comparison with the anti-M2e peptide pAb.  
MATERIALS AND METHODS 
Production of recombinant M2e proteins (rM2e) 
The synthetic M2e gene (M2eC0) was used to 
generate fifteen M2e mutant genes (M2eC1 to 
M2eC15) by introducing various mutations at specific 
sites (Sumarningsih, 2011). These fifteen M2e genes 
were cloned into pMAL-P4x expression vector and 
transformed into E. coli BL21 DE3 cell (BioLine Pty 
Ltd, Alexandria, NSW) to express recombinant M2e-
MBP proteins, referred to as rM2e (C1 to C15). After 
cold osmotic shocked, the expressed proteins were 
purified with amylose resin beads (New England 
Biolabs, UK), and analysed by polyacrylamide gel 
electrophoresis in sodium dodecyl sulfate (SDS-PAGE) 
for the size and purity. 
Synthetic M2e peptide 
All M2e peptides (C1 to C18) were synthetized by 
GenScript (Piscataway, New Jersey, USA) 
corresponding to the sequences of M2e mutants (Table 
1) with purity varied from 79% to 94%. The M2eC15 
peptide was not synthesized because it had homolog 
sequence to that of M2eC14. The M2eC17 peptide was 
also not included in this study because the synthesis 
was unsuccessful even after three different attempts by 
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GenScript. In initial study, M2eC0 peptide was 
purchased from Peptide 2.0 (Chantilly, VA, USA). All 
these seventeen peptides (C0 to C18) were dissolved in 
sterile ddH2O (1mg/ml) and diluted in 1:1 with sterile 
glycerol and stored at -20°C. 
Anti-M2 monoclonal antibody 14C2 and anti-M2e 
polyclonal antibodies 
Mouse monoclonal antibody (mAb) 14C2 was 
purchased from Abcam, (Sapphire BioScience Pty Ltd, 
NSW) as ascetic fluid. The mAb 14C2 was generated 
against the M2 protein of Influenza A Virus A/WSN/33 
following live inoculation. In this study, mAb 14C2 
was optimised by ELISA titration using M2eC3, 
M2eC4 and M2eC11 peptides to determine the optimal 
dilution for mAb 14C2 in WB and ELISA. 
Anti-M2e polyclonal antibodies (pAb) were 
produced in chicken and rabbit immunized using 1 mg 
of M2eC0 peptide in complete Freund’s adjuvant, 
followed by 2 mg, 4 mg and 8 mg of M2eC0 peptide 
with incomplete Freund’s adjuvant (as a second, third 
and fourth immunisation, in 3 weeks intervals). 
Chicken and rabbit were bled prior to each 
immunisation and the pAb were tested in M2eC0 
peptide ELISA to determine the titres. The sera were 
harvested after the third immunisation when the 
optimum titres of pAb were found. 
Western blot (WB)  
All sixteen rM2e proteins (C0 to C15) were 
subjected by polyacrylamide gel electrophoresis in 
sodium dodecyl sulfate (SDS-PAGE) and then 
transferred to polyvinylidene difluoride (PVDF) 
membrane. The membrane was washed two times using 
PBS-T (0.5% Tween in PBS) and incubated in blocking 
buffer (5% skim milk in PBS) for 1.5 hours. All 
incubations for WB were performed at room 
temperature. After washing two times, the membrane 
was incubated with diluted primary antibody for 1 
hour, washed five times, and incubated with diluted 
HRP-conjugated antibody for 1 hour. Different 
antibody dilution was used for each WB. First WB used 
dilution at 1/5000 for mAb14C2 and 1/2000 for HRP- 
rabbit anti mouse IgG. Second WB used dilution at 
1/2000 for rabbit pAb and 1/2000 for HRP-goat anti 
rabbit IgG. Third WB used dilution at 1/1000 for 
chicken pAb and 1/4000 for HRP-rabbit anti chicken 
IgG. The antigen-antibody interaction was visualized 
using Amersham enhanced chemiluminescent (ECL) 
western blotting detection reagents (GE Healthcare 
Australia Pty Ltd, Rydalmere, NSW). The membrane 
was exposed to blue rite autorad film (Astral Pty Ltd, 
Gymea, NSW) and scanned to measure the band mass 
by Kodak molecular imaging software. 
Value of 100% was given for the band intensity of 
homologous M2e sequence between antibody and 
antigen use in each WB. The band intensity for 
antibody binding to other M2e proteins was then 
compared to the homologous M2e reaction and 
expressed as a percentage of binding. Decrease in band 
intensity of a minimum of 25 to 30% was indicative the 
reduction in antibody binding. 
Enzyme-linked immunosorbent assay (ELISA) 
All the procedures for ELISA were performed at 
room temperature. Both ELISA used antigen 
concentration at 0.6ng/well for rM2e proteins and M2e 
peptides, which dissolved in carbonate-bicarbonate 
buffer (pH 9.6) and coated into each well of microtitre 
plate (NUNC Maxisorb). After coating for overnight, 
the plate was washed once with PBS-Tween 0.05% 
(PBS-T). Then 150μl/well of blocking buffer (5% 
Newborn Calf Serum in PBS-T) was added and 
incubated for 2 hours. After washing two times, 
100μl/well of diluted antibody was added and the plate 
was incubated for 1 hour. Similar dilution at 1/2000 
was used for all antibodies (mAb14C2, chicken pAb 
and rabbit pAb) in rM2e ELISA. But the dilution used 
in M2e-Peptide ELISA was different, which was 
1/4000 for mAb14C2 and rabbit pAb; and 1/2000 for 
chicken pAb. After incubated with antibody, the 
microplate was washed five times, followed by 
incubation with 100μl/well of diluted HRP-antibody for 
1 hour. The dilution at 1/2000 was used for HRP-rabbit 
anti mouse IgG and HRP-goat anti rabbit IgG, and at 
1/4000 dilution for HRP-rabbit anti chicken IgG. After 
washing five times, 100μl/well of 3,3’ ,5,5’-
tetramethylbenzidine (TMB) susbtrate (Sigma Aldrich 
Pty Ltd, Castle Hill, NSW) was added and incubated 
for 15 minutes. The reaction was stopped by adding 
25μl/well of 2M H2SO4. The binding of antibody to 
antigen was determined based on the optical density 
(OD) using microplate reader at a wavelength of 
450nm (OD450). 
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Table 1. Amino acid sequences for the parent and mutant genes of M2e 
M2e Parent (a)                                  Amino acid sequence 
 Mutant (b) , Peptide (c)  
C1 C0 (a)         MSLLTEVETP TRNEWECKCS DSSD 
 C1 (b,c)         .......... ...G...... .... 
C2 C1 (a)         MSLLTEVETP TRNGWECKCS DSSD 
 C2 (b,c)         .........L .......... .... 
C3 C1 (a)         MSLLTEVETP TRNGWECKCS DSSD 
 C3 (b,c)         .......... I......... .... 
C4 C3 (a)         MSLLTEVETP IRNGWECKCS DSSD 
 C4 (b,c)         .......... ..K....... .... 
C5 C0 (a)         MSLLTEVETP TRNEWECKCS DSSD 
 C5 (b,c)         .......... .......R.. .... 
C6 C5 (a)         MSLLTEVETP TRNEWECRCS DSSD 
 C6 (b,c)         .......... ...G.G.... .... 
C7 C6 (a)         MSLLTEVETP TRNGWGCRCS DSSD 
 C7 (b,c)         .........L .......... .... 
C8 C6 (a)         MSLLTEVETP TRNGWGCRCS DSSD 
 C8 (b,c)         .........H .......... .... 
C9 C7 (a)         MSLLTEVETL TRNGWGCRCS DSSD 
 C9 (b,c)         .......... .K........ .... 
C10 C5 (a)         MSLLTEVETP TRNEWECRCS DSSD 
 C10 (b,c)         .......... I......... .... 
C11 C10 (a)         MSLLTEVETP IRNEWECRCS DSSD 
 C11 (b,c)         .......... .....G...N .... 
C12 C1 (a)         MSLLTEVETP TRNGWECKCS DSSD 
 C12 (b,c)         .......... ..S....... .... 
C13 C3 (a)         MSLLTEVETP IRNGWECKCS DSSD 
 C13 (b,c)         .......... .......R.. .... 
C14* C5 (a)         MSLLTEVETP TRNEWECRCS DSSD 
 C14 (b,c)         .......... ...G...... .... 
C15* C2 (a)         MSLLTEVETL TRNGWECKCS DSSD 
 C15 (b)         .........P .......R.. .... 
C16 C16 (c)         MSLLTEVETP TRNEWECKCI DSSD 
C18 C18 (c)         MSLLTEVETS TRNEWECRCS DSSD 
a) The M2e parent gene used as a template in mutagenesis 
b) The M2e mutant gene, product of mutagenesis for rM2e protein expression 
c) The M2e sequence for synthetic peptide use in this study 
*The sequence of C14 and C15 mutant genes were similar but generated from different parent genes 
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RESULTS AND DISCUSSION 
The M2e based DIVA test has been considered as 
the test of choice for use in surveillance of vaccinated 
flocks in Indonesia in order to estimate the extent of 
H5N1 challenge in vaccinated flocks and to establish 
zones that are free from H5N1 (Tarigan et al. 2015; 
Wibowo et al. 2017). Although the M2e based DIVA 
test has been evaluated for possible use in commercial 
poultry, very little is known about the antigenicity of 
M2e and its specificity to detect infections caused by 
avian influenza virus (AIV). 
The M2e protein has been considered as a highly 
conserved protein among all influenza A virus (IAV) 
strains and subtypes. For this reason M2e has been 
studied as a possible candidate for a universal IAV 
vaccine (Schotsaert et al. 2009) and also as a potential 
DIVA diagnostic antigen to detect exposure to different 
AIV subtypes (Kim et al. 2010; Lambrecht et al. 2007). 
However, in several studies that have focused on M2e 
from human IV strains, evolution and mutation at some 
amino acid positions in the M2e have been reported 
(Furuse et al. 2009; Ito et al. 1991). Also, data obtained 
following the emergence and spread of H5N1 and 
additional surveillance in wild birds have further 
indicated that the M2e protein may also be under the 
similar selection pressure as are the HA and the NA 
proteins (Lam et al. 2008). The M2e amino acid 
variability has also been reported in other studies to 
occur in the middle part of M2e that potentially could 
have an affect on its antigenicity (Liu & Chen 2005; 
Wang et al. 2009). Ito et al. (1991) reported high M2 
variation between positions 10 to 28, whereas the first 
nine amino acids (1MSLLTEVET10) were highly 
conserved. In this study, the amino acid variation in the 
M2e protein of different strains of H5N1 and of other 
frequently isolated AIV subtypes were determined. The 
most common mutations were identified for generation 
of recombinant M2e protein to be used for antigenic 
mapping of the M2e. 
The antigenicity of a protein is strongly associated 
with the hydrophobicity, 17 M2e amino acid sequence 
were designed (Table 1) based on the hydrophobicity 
differences, so that each sequence had between one and 
five selected mutations in comparison to the rM2eC5 
sequence (A/Ck/Indo/BL/03 H5N1 strain). These rM2e 
proteins had different hydrophobicity values, which 
indicating the potential of each amino acid position 
contribute to the M2e antigenicity (result not shown). 
Peptides analogous to these   sequences were 
synthetized and labeled as M2eC0, M2eC1, etc. 
Antigenic mapping of M2e was performed by testing 
the binding of polyclonal and monoclonal antibody to 
each rM2e proteins in WB and ELISA, and to M2e-
peptides in ELISA. 
Antigenic mapping using anti-M2 monoclonal 
antibody 14C2 (mAb 14C2)  
Monoclonal antibody 14C2 was used in this study to 
compare the M2e antigenicity because it was 
previously shown to specifically recognise amino acid 
isoleucine at the position 11 (Zebedee & Lamb 1988). 
The mAb 14C2 was generated against the M2 protein 
of human influenza virus A/WSN/33/H1N1 strain, and 
WB result (Figure 1a) showed that mAb 14C2 reacted 
strongly with rM2eC11 (homologous reaction), which 
has similar sequence to M2e of A/WSN/33-H1N1 
virus. Introduction of two mutation G16E and N20S 
into rM2eC10 was used to generated rM2eC11, and the 
WB of rM2eC10 showed that amino acid different in 
these positions caused a reduction in mAb 14C2 
binding to 60%. MAb14C2 also reacted with rM2eC3, 
rM2eC4 and rM2eC13, that all having isoleucine at the 
position 11 (11I), but this reaction was lesser in 
comparison to the homologous reaction, indicating that 
changes at other positions (E14G, G16E and R18K) 
could reduce the binding of mAb14C2. The binding to 
rM2eC4 and rM2eC13 with additional change (E14G) 
was further reduced to 40% and 35%, respectively. The 
reduction to rM2eC3, which similar to rM2eC13 
(35%), showed that amino acid change at R18K did not 
affected the binding of mAb 14C2. Additional mutation 
(I11T) in rM2eC0, rM2eC1, rM2eC14 and rM2eC15 
completely abrogated the mAb 14C2 binding to these 
M2e proteins. 
In WB of rM2eC5, to which mAb 14C2 did not 
bind, when T11I was mutated back generating the 
rM2eC10, the binding of mAb 14C2 was restored, but 
only to 60% of binding, its indicating clearly different 
contribution of positions 11, 16, and 20 to mAb 14C2 
binding. Although four constructs rM2eC2, rM2eC7, 
rM2eC8, and rM2eC9 had additional P10L change, the 
contribution for this position to M2e antigenicity was 
not possible to assess because there was no rM2e 
proteins containing aa differed from rM2eC11 at 
position 10 only. 
ELISA of mAb 14C2 using rM2e proteins showed 
similar result as WB (Figure 1.b.). The binding was 
only found with rM2eC3, rM2eC4, rM2eC10, 
rM2eC11 and rM2eC13, which contain isoleucine at 
the position 11 (11I). However, the binding to rM2eC3 
and rM2eC4 was reduced in comparison to rM2eC10, 
rM2eC11 and rM2eC13, indicating that change at 
position 18 (R18K) could have affected the antibody 
binding. MAb 14C2 also did not react in ELISA with 
rM2eC0, rM2eC1, rM2eC5, rM2eC6, rM2eC7, 
rM2eC8, rM2eC9, rM2eC12, rM2eC14 and rM2eC15, 
and all these rM2e had amino acid change at position 
11 (I11T).  
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Figure 1.  Antibody binding analysis of mAb 14C2 to rM2e proteins in WB (a); mAb 14C2 to rM2e proteins in ELISA (b); and mAb 14C2 to 
M2e peptides in ELISA (c). Amino acid variations between rM2e proteins to rM2eC11 (*) were shown in the table.  
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Figure 2. Analysis of mAb 14C2 titre in ELISA using three different M2e peptides (M2eC3, M2eC4 and M2eC11). M2eC11 peptide has the 
homologous sequence to human influenza A virus A/WSN/33/H1N1 strain used to generate mAb 14C2. 
Similar finding was obtained in ELISA with M2e-
peptides (Figure 1.c), mAb 14C2 strongly reacted with 
all five M2e peptides (M2eC3, M2eC4, M2eC10, 
M2eC11 and M2eC13) that had isoleucine at the 
position 11, and there was no influence of other amino 
acid changes to this binding. Positive but low reactions 
of mAb 14C2 binding was also found with M2eC0 and 
M2eC5 peptides which had threonine at the position 11 
(I11T) and had only one common amino acid change in 
comparisons to the homologous sequence (rM2eC11) at 
position 20 (N20S). In this study, mAb 14C2 was 
titrated on the M2eC11, M2eC3 and M2eC4 peptides 
(Figure 2) because the binding of mAb 14C2 to M2eC3 
and M2eC4 peptide in ELISA differed from the 
previous result of WB. As shown, there was a 
difference in binding between these three M2e peptides 
at the lower concentration of mAb 14C2, indicating 
that M2eC3 (E14G, G16E, K18R, S20N) and M2eC4 
(N13K, E14G, G16E, K18R, S20N) differed 
antigenically from M2eC11. 
Antigenic mapping using anti-M2e rabbit polyclonal 
antibody  
To investigate if there was any different M2e 
antibody response between species of animal 
immunized, rabbit polyclonal antibody to the M2eC0 
peptide were used in this study to characterise the M2e 
antigenicity. Strong reactions of rabbit M2e antiserum 
were detected in WB (Figure 3.a) with rM2eC0 and 
rM2eC1 (E14G), rM2eC13 (T11I, E14G, K18R), 
rM2eC14 (E14G, K18R) and rM2eC15 (E14G, K18R) 
indicating that changes at the position T11I, E14G, and 
K18R did not influence its binding. The results also 
showed a complete absence of reaction of rabbit pAb 
with M2eC2, M2eC7, M2eC8 and M2eC9 that had 
either P10L or P10H amino acid change. These two 
changes at position 10 (P10L or P10H) caused the lack 
of binding equally. It was of interest that amino acid 
change at position 11 in rM2eC3, rM2eC4, rM2eC10, 
rM2eC11 and rM2eC13 did not influence the binding 
of anti-M2e rabbit pAb, nor did the amino acid changes 
at the position E14G, G16E and K18R and S20N. 
ELISA results using rM2e proteins (Figure 3.b) 
showed less discriminating value compare to WB. It 
showed that the highest reaction of rabbit pAb was with 
the homologous rM2eC0 protein, the binding was 
reduced to M2eC2, M2eC7 and C9 with changes at 
position P10L. Result of ELISA M2e-peptide was in 
agreement with the WB and ELISA rM2e for most 
peptides (Figure 3.c). Rabbit pAb reacted less with 
M2eC2, M2eC7, M2eC8, M2eC9 and M2eC18, these 
all peptides has amino acid different to M2eC0 at 
position 10 (P10L, P10H and P10S). The differences of 
antibody binding to M2e were visible only at high 
dilution (1/4000 concentration) of rabbit pAb indicating 
the influence of rabbit pAb concentration for 
differentiation capacity. 
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Figure 3. Antibody binding analysis of anti-M2e rabbit pAb to rM2e proteins in WB (a); anti-M2e rabbit pAb to 
rM2e proteins in ELISA (b); and anti-M2e rabbit pAb to M2e peptides in ELISA (c). Amino acid 
variations between rM2e proteins to rM2eC0 (*) were shown in the table. 
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Figure 4.  Antibody binding analysis of anti-M2e chicken pAb to rM2e proteins in WB (a); anti-M2e chicken pAb 
to rM2e proteins in ELISA (b): and anti-M2e chicken pAb to M2e peptides in ELISA (c). Amino acid 
variations between rM2e proteins to rM2eC0 (*) were shown in the table. 
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Antigenic mapping using anti-M2e chicken 
polyclonal antibody  
Anti-M2e chicken polyclonal antibody was also 
used in this study to analyse the M2e antigenicity. WB 
result showed chicken pAb (Figure 4.a) was strongly 
reacted with the homologous rM2eC0 and other rM2e 
proteins, including rM2eC1 (E14G), rM2eC3 (T11I and 
N13S), rM2eC5 (K18R) rM2eC10 (T11I and K18R) 
and rM2eC11 (T11I, E16G, E14G, K18R and S20N). 
This finding suggested that changes at the position 
T11I, E14G, E16G, K18R and S20N did not influence 
the binding of chicken pAb. In contrast, chicken pAb 
was not reacted or weakly reacted with rM2eC7 and 
rM2eC9 that had amino acid change at the position 10 
(P10L), rM2eC12 (N13S & E14G), and rM2eC13 
(T11I, E14G and K18R). There was also some 
reduction of antibody binding to rM2eC2 (P10L and 
E14G), rM2eC14 and rM2eC15 (E14G and K18R), 
which indicate that the change at position 13 (N13S) as 
well as position 14 and 18 (E14G and K18R) also 
affected the antibody binding when present 
simultaneously. 
Similar result was obtained from rM2e ELISA, it 
showed the importance of amino acid changes at 
position 10 (P10L) and 13 (N13S) (Figure 4.b) for 
chicken pAb binding. The binding of chicken pAb to 
rM2eC1 (E14G), rM2eC3 (T11I, E14G), rM2eC4 
(T11I, R13K, E14G,) rM2eC6 (E14G, E16G, K18R) 
and rM2eC14 (E14G, K18R) was reduced significantly 
(>50%), indicating that changes of amino acid T11I, 
N13S or N13K, E14G, E16G and K18R, had disturbed 
antigenicity of the M2e, although it has a lesser degree 
compare to the changes of P10L and N13S.  
Analysis using M2e-peptides ELISA (Figure 4.c) 
was in complete agreement with WB result, it showed 
significant reduction of chicken pAb binding to 
M2eC2, M2eC7 and M2eC12 peptide. These M2e 
peptides had a common amino acid change at position 
10 (P10L), 13 (N13S) and 14 (E14G). The antibody 
binding to M2eC18, which has P10S change, was also 
abrogated. The M2e peptide ELISA indicated the 
important amino acid for chicken pAb were located at 
position 10, 11, 14 and 18.  
 
Table 2. Summary of the important amino acid changes influenced the antibody (mAb 14C2, rabbit pAb, chicken 
pAb) binding to rM2e in WB, rM2e-ELISA and M2e-peptide ELISA. 
Antibody rM2e-WB 
                            ELISA 
rM2e M2e-Peptide 
mAb 14C2 P10L, H P10L, H P10L, H, S 
 I11T I11T I11T 
 E14G E14G E14G 
 G16E G16E G16E 
Rabbit pAb P10L, H P10L, H P10L, H, S 
   T11I 
   N13K, S 
 E14G  E14G 
 E16G  E16G 
Chicken pAb P10L P10L, H P10L, H 
  I11T I11T 
 N13S N13S E14G 
  E14G  
  K18R K18R 
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Anti-M2 mAb 142C and anti-M2e pAb (chicken 
and rabbit) were used in this study to determine the 
antigenic epitopes on the M2e protein and the result 
showed that all three antibodies identified the same 
immunodominant epitopes, although chicken pAb had 
broader specificity and recognised additional antigenic 
epitopes on the M2e which were not recognised by 
rabbit pAb and mAb 14C2. Overall, all antigenic 
epitopes identified were located between amino acid 
position 10 and 18 (Table 2). Single amino acid 
changes at positions 10, 11, 13 and 18 have affected the 
binding, with amino acid changes at position 14 and 16 
possibly acting co-operatively. It was considered that 
the entire region between amino acid 10 and 18 form a 
part of a single epitope in which amino acid changes at 
the position 10, 11 and 13 effect the binding and lead to 
the lack of recognition by an antibody. Both chicken 
and rabbit pAb used in this study contained high titres 
of anti-M2e antibodies and indicating that the synthetic 
M2eC0 peptide inoculated with Freund adjuvant was 
immunogenic and could induced high titre of 
antibodies recognised by both rM2e proteins and 
synthetic M2e peptides. High antibody titres 
(>1/32000) for rabbit and chicken M2e pAb were 
detected in ELISA (result not shown). 
M2e protein has been reported as a poor 
immunogen and induced low or no detectable antibody 
titres following live infection in humans (Fiers et al. 
2004). The antibodies titres from animals or humans 
infected with IAV were found to be in low titres and of 
short duration (Feng et al. 2006).  However, it has been 
shown that the M2e synthetic peptide or recombinant 
M2e protein could induce high titre of antibody in mice 
and it can bind to the M2e in the surface of MDCK 
cells infected by PR8 IAV (Wu et al. 2007). When 
inoculated as a free peptide, M2e induced low (<100) 
antibody response in mice (Xia et al., 2011), but this 
immunogenicity was improved by pairing M2e with 
certain carrier proteins, such as hepatitis B virus core 
protein, Freund’s adjuvant, the Norovirus P particle and 
other immunomodulators (Wu et al. 2007; Xia et al. 
2011; Li et al. 2011). The number of M2e polyclonal 
antibodies have been produced and used to study M2e 
antigenicity (Frace et al. 1999; De Filette et al. 2006). 
From direct comparisons of binding to rM2e, two 
antigenic sites were associated with the positions 10 
and 13. Amino acid change at position 10, either P10L 
or P10S, reduced the antibody binding significantly, 
indicating that significant proportion of antibodies is 
directed towards this epitope. Therefore, position 10 is 
considered as an immunodominant epitope for M2e. At 
the same position, amino acid change P10H had less 
impact on antibody binding. It was evident that by 
introduction of a single mutation P10H in M2eC6 to 
generate M2eC8, the binding of antibody to the mutant 
M2eC8 did not change significantly. The amino acid 
change at the position 13, either N13K or N13S, also 
reduced antibody binding significantly and could 
therefore be considered as an immunodominant 
epitope. When comparisons were made between the 
parent and the mutant M2e, contribution of other amino 
acid changes to the antigenicity of the M2e became 
evident. In particular, the change at the position 14 
(E14G) was the most common change between M2e of 
AIV and caused reduction in antibody binding. In M2e 
protein with amino acid E14G, additional E16G 
mutation further reduced antibody binding indicating 
these two positions might be the part of the same 
epitope. Another common amino acid change K18R 
was also reduced the antibody binding, but this was not 
a consistent finding. In M2e-peptide ELISA using 
chicken pAb, antigenic differences between proteins 
were less evident, with amino acid changes P10L and 
P10S significantly influencing the binding of antibody. 
Two other amino acid changes that marginally affected 
the binding of antibody were E14G and K18R. It is 
consider that the antigenicity differences between rM2e 
proteins and M2e peptide are due to the higher affinity 
of anti-M2e pAb for peptide than for rM2e protein, 
resulting in antibody having high titres and less 
discriminating ability for minor antigens present in a 
peptide.  
Analysis using rabbit pAb indicated that the only 
amino acid changes that influence the binding were 
P10L, P10H or P10S. These changes caused the lack of 
binding equally, which was contrary to the results with 
chicken pAb. The reason for lesser discriminating value 
of rabbit pAb in comparison to chicken pAb obtained 
by the same immunisation is speculative. Both sera 
have been obtained by immunisation with the same 
peptide and adjuvant, and titres were comparable. 
While antigenic presentation of immunizing M2e 
peptide should be the same in both rabbit and chicken, 
it is possible that chicken, as a natural host for AIV, is 
more capable to recognise minor antigenic differences 
and mount an effective immune response. Rabbits have 
been often used to produce antibody against avian 
pathogen, including against purified antigens, in which 
case usually it generate broadly reactive antibody 
response.  
Unlike for chicken and rabbit pAb, the dominant 
epitope detected by mAb 14C2 was isoleucine at the 
position 11. The highest reaction of mAb 14C2 was 
found with the M2eC11 (figure 1.a), which has 
isoleucine at position 11 (11I) and homologous 
sequence to M2e of A/WSN/33 IAV. However, less 
reaction was found with other M2e (M2eC3, M2eC4, 
M2eC10 and M2eC13), which also had isoleucine at 
position 11. This indicates that changes at other 
positions (E14G, G16E and R18K) could also have 
affected and reduced the binding of mAb 14C2 to M2e. 
Previously, the M2e protein antigenic sites have been 
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determined to be located in the middle part of M2e, 
which was in the first ten amino acids at the N-terminal 
end of M2e (Fu et al. 2009). Also, study using mouse 
mAb 8C6 suggested that the M2e antigenic determinant 
was located between amino acid residues 8 to 12 (8-
ETPIR14) (Zou et al. 2005). MAb 8C6 was also 
reported can not recognise 7-mer M2e peptide 
containing amino acid substitution either at position 9 
(T9A), 12 (R12A) or both positions 9 and 12 (T9A; 
R12A) (Zou et al. 2008). A panel of M2e human 
recombinant monoclonal antibodies have also been 
used for M2e antigenic study and showed that different 
M2e epitopes, SLLTEVETPIRNEWG, 
LLTEVETPIRNEWG, LLTEVETPIR, and TPIRNE 
were recognised by monoclonal antibody L66, N547, 
Z3G1, and C40G1, respectively (Wang et al. 2008). 
Hence, different results could have been obtained since 
every monoclonal antibody could only recognise one 
often-discrete epitope (Zhang et al. 2006). 
In the present study, the M2e specific mouse mAb 
14C2 was used to analyse the M2e antigenicity. WB 
and ELISA results showed that amino acid substitution 
at the position 11 (I11T) could destroy the M2e 
antigenicity. This result was similar to the earlier study 
(Zebedee & Lamb 1988) used mAb 14C2 on 
immunoprecipitation and immunoblot assays, and it 
showed eight different M2 proteins from heterologous 
IAV containing different amino acids at the position 11 
(I11T) could not be recognised by mAb 14C2. This 
finding indicates that mAb 14C2 specifically binds to 
isoleucine at the position 11. The important of 
isoleucine at position 11 as immunodominant epitope 
for M2e also reported by study using human mAb 8C6, 
which specific for the M2e with sequence 5-
EVETPIRN-14, it showed that mAb 8C6 weakly 
reacted with GST-5- EVETPTRN-14 (Liu & Chen 
2005). The same study also reported that the residue 10 
was the most important amino acid for the M2e 
antigenicity, that human mAb 8C6 could not bind to 
GST-EVETLTRN (Liu & Chen 2005). This finding 
was supported by previous study, which reported the 
influenza A virus escape mutant with mutation at 
position 10 (P10L and P10H), found in mice infected 
using PR8 influenza A virus and treated with mAb 
14C2 (Zharikova et al. 2005).  
CONCLUSION 
In summary, the study showed that the M2e 
antigenic sites are located between residues 10 – 18 and 
amino acid changes at these sites may all affect the 
antibody binding to M2e protein. It also identified that 
the capacity for antigenic mapping of the M2e protein 
was different between antibody raised in chicken and 
rabbit. Isoleucine position 11 is crucial for antibody 
binding of mAb 14C2 to M2e. However, the critical 
amino acid changes for rabbit pAb and chicken pAb 
binding was proline at position 10. Therefore, these 
positions 10 and 11 can be considered as the important 
immunodominant epitopes for M2e. 
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